Clinical Trial Search

Primary: Number of Participants Classified as Upper Limb Responders on the 9 Hole Peg Test (9HPT) — 4; 3; 58; 59 Participants

Primary: Difference Between Active and Placebo for Time Matched Baseline Adjusted Mean QTcF — -9.7; -9.2; 6.1 milliseconds

Primary: Number of Participants With Related Clinical Signs or Symptoms at Baseline — 63; 63 Participants — p=<0.01

Primary: Evaluate the Occurrence and Severity of Treatment Emergent AEs. — 13; 9; 2; 2 participants

Primary: Number of Participant With Treatment-Related Adverse Events as Assessed by CTCAE V4.03, All of Observed and Self-reported AEs Affected, by Treatment Regimen. — 6; 2…

Primary: Number of Participants With Vaginal Delivery Within 24 Hours — 50; 55 Participants

Primary: Change in Body Weight (%) — -16.5; -5.8; -17.6; -6.1 Percentage — p=<.0001

Primary: Tumor Response — 22 Participants

Primary: Serum Concentration of Tramadol and Tramadol Metabolites With Respect to Metabolic Phenotype — 372.7; 7.05; 17.1; 40.9 mcg/L

Primary: Number of Incidence Rate (IR) of Adverse Events, Serious Adverse Events and Death Per 100 Patient-years in Participants — 873; 451; 59; 25 IR/100 patient-years

Primary: Number of Dose Limiting Toxicity Events — 0; 0 Dose Limiting Toxicity Events

Primary: Prevalence of a History of Cardiovascular Disease (CVD) Among Swedish Patients With Type 2 Diabetes Mellitus (T2DM) Who Were Alive on 31st of December 2017 — 130508…

Primary: Change in Hamilton Depression Rating Scale (HDRS) Scores — -9.27; -9.40 units on a scale — p=0.3

Primary: Maximum Plasma Concentration (Cmax) of Total Dabigatran and of Free Dabigatran Following a Single Dose in Participants Without and With Concomitant Quizartinib — 192…

Primary: Changes in End Diastolic and End Systolic Volume as Measured by Standard and Advanced MRI Parameters — 3.3; 3.0; 3.0; 4.4 ml